



For immediate distribution
Source: DIAGNOS inc.

2012.03.14

DIAGNOS Announces Contract with a Major Global Pharma in the UAE

Brossard, Quebec, Canada – March 14, 2012 - DIAGNOS inc. (“DIAGNOS” or “the Corporation”) (TSX Venture: ADK), leader in algorithm development, data analysis, and image processing, announces today the signing of an agreement with a major global pharmaceutical partner, for the joint deployment and usage of CARA in the United Arab Emirates.

As part of its mission to discover, develop and successfully market innovative products to prevent and cure diseases, to ease suffering and to enhance the quality of life, our partner organization supports various health organizations and health initiatives, including population screening, in the United Arab Emirates. The partner organisation views our CARA screening platform as an excellent tool within the context of their activities in UAE and the Middle East. Their lead ophthalmology product is indicated for a variety of ophthalmic complications including those associated with diabetes, and with our assistance they hope to slow or reverse vision impairment in a larger patient population.

“Recognizing the elevated rate of diabetes and its complications in the area, we have been involved in projects in the region for some time now, and are in a position to materially and constructively help local authorities with critical screening projects. Our Partner’s leadership and support will make these initiatives feasible and will undoubtedly greatly benefit the local population. We are very excited with this important relationship.” Said Peter Nowacki, Diagnos’ Vice-President – Healthcare.

“Under the terms of the present agreement, DIAGNOS will conduct a series of pilot deployments, at \$9 per patient exam, within the UAE including both stationary and mobile applications with the objective to determine the best CARA deployment model for both organizations and their local partners, and to scale-up subsequently within the UAE and the Middle East. We are presently working on putting in place relationships of a similar nature in certain areas in Europe.” Said Andre Larente, Diagnos’ President.

About CARA

CARA is a tele-ophthalmology platform that integrates with existing equipment (hardware and software) and processes at the point of care (POC) and comprises: image upload, image enhancement automated pre-screening, grading by a specialist, and referral to a specialist. CARA’s image enhancement algorithms make standard retinal images sharper, clearer, and easier to read. CARA is accessible securely over the internet, and is compatible with all recognized image formats and brands of fundus cameras, and is EMR compatible. CARA is a cost-effective tool for screening large numbers of patients, in real-time and has been approved by regulatory authorities including Health Canada, US Food and Drug Administration, and the European Union.

About DIAGNOS

Founded in 1998, DIAGNOS is a publicly traded Canadian corporation with a mission to commercialize technologies combining contextual imaging and traditional data mining thereby improving decision making processes. DIAGNOS offers products, services, and solutions to clients in a variety of fields including healthcare and natural resources.

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this press release.

For further information, please visit our website at www.diagnos.com or the SEDAR website at www.sedar.com. You may also contact our investor relations representative:

André Larente, President
DIAGNOS inc.
Tel.: 1-877-678-8882 or (450) 678-8882, ext.: 224
alarente@diagnos.com

Louis Morin
Bid Capital Markets
Tel.: 514-845-1101
bidcapital@videotron.ca